Related Experiment Video
Updated: Apr 30, 2026
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
Anti-galectin-3 therapy: a new chance for multiple myeloma and ovarian cancer?
Leonardo Mirandola1, Diane D Nguyen, Rakhshanda L Rahman
11Department of Internal Medicine at the Division of Hematology & Oncology, Texas Tech University Health Sciences Center and Southwest Cancer Treatment and Research Center, Lubbock, TX, USA.
Abstract:
Here we review the role of Galectins in the molecular pathogenesis of multiple myeloma and ovarian cancer, with a special focus on Glectin-3. Multiple myeloma is the second most common hematologic malignancy worldwide. Because the pathogenesis of multiple myeloma is still incompletely understood, there is no ultimately effective cure, and this cancer results fatal. Ovarian cancer is the most lethal gynecologic malignancy worldwide. Due to the lack of screening techniques for early detection, patients are mostly diagnosed with advanced disease, which results ultimately fatal. Multiple myeloma and ovarian cancer have different biologies, but they share a strong dependence on adhesion with extracellular matrix and other cells. Galectin-3 plays a key role in regulating such adhesive abilities of tumor cells. Here we discuss the outcomes and possible mechanism of action of a truncated, dominant negative form of Galectin-3, Galectin-3C, in these malignancies. Overall, we report that Galectin-3C is a promising new compound for effective adjuvant therapies in advanced, refractory multiple myeloma and ovarian cancer.
Insights
Galectin-3C shows promise as an adjuvant therapy for advanced multiple myeloma and ovarian cancer. This compound targets tumor cell adhesion, a key factor in these fatal malignancies.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Multiple myeloma and ovarian cancer are leading causes of cancer mortality worldwide.
- Their pathogenesis remains incompletely understood, necessitating novel therapeutic strategies.
- Both malignancies exhibit a significant dependence on cell adhesion processes.
Purpose of the Study:
- To review the role of Galectins, particularly Galectin-3, in the molecular pathogenesis of multiple myeloma and ovarian cancer.
- To discuss the therapeutic potential of a dominant-negative form of Galectin-3, Galectin-3C, in these cancers.
Main Methods:
- Review of existing literature on Galectins, multiple myeloma, and ovarian cancer.
- Focus on the function of Galectin-3 in regulating tumor cell adhesion.
- Analysis of studies investigating Galectin-3C's outcomes and mechanisms.
Main Results:
- Galectin-3 plays a critical role in regulating tumor cell adhesion in both multiple myeloma and ovarian cancer.
- Galectin-3C demonstrates promising therapeutic outcomes in preclinical models of these malignancies.
- The compound's mechanism of action involves interfering with key adhesive interactions.
Conclusions:
- Galectin-3C represents a potential novel therapeutic agent for advanced, refractory multiple myeloma and ovarian cancer.
- Targeting Galectin-3-mediated adhesion may offer a new avenue for adjuvant cancer therapy.
- Further research into Galectin-3C is warranted to explore its clinical utility.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
01:27Tumor Immunotherapy